Overview:
Advancements in understanding the molecular drivers of adult and pediatric gliomas, including alterations in IDH, H3, BRAF, and other actionable targets, have paved the way for a rapid expansion of personalized treatment options across the glioma spectrum. However, translating comprehensive molecular profiling into timely, evidence-based treatment decisions remains challenging because of heterogeneity in testing practices, evolving therapeutic targets, and limited familiarity with recently approved agents and emerging clinical trial data.
This live/virtual hybrid Tumor Board–style symposium will bring
together experts in the management of adult and pediatric gliomas to discuss
novel targeted and molecularly guided therapies through real-world case
reviews. Faculty will provide an overview of key molecular profiles and
biomarkers in low-grade and high-grade gliomas, address persistent unmet needs
in the care of both adult and pediatric patients, and highlight innovative,
tailored approaches that are reshaping the future of glioma management. Case-based
discussions will help clinicians interpret molecular testing results, compare
emerging targeted options for distinct glioma subtypes, and develop practical
strategies to integrate recently approved and investigational therapies into
clinical practice to optimize outcomes for patients with these tumors.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Integrate current classification criteria and diagnostic strategies for identifying adult and pediatric patients with glioma
- Incorporate genetic and molecular information to classify gliomas and develop personalized treatment plans accurately
- Evaluate the data for recent advancements in targeted agents, immunotherapies, and other innovative treatment methods for treating patients with gliomas
- Identify strategies to integrate targeted therapies, immunotherapies, and novel emerging treatment approaches for managing pediatric patients with gliomas.
Target Audience:
This educational activity is directed toward physicians,
nurses, NP/PAs, and other HCPs involved in the treatment and management of
gliomas.
